Trials / Completed
CompletedNCT00036660
SarCNU in Treating Patients With Recurrent Malignant Glioma
A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- NCIC Clinical Trials Group · Network
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent malignant glioma.
Detailed description
OBJECTIVES: * Determine the efficacy of SarCNU, in terms of objective response and duration of response, in patients with recurrent malignant gliomas. * Determine the qualitative and quantitative toxic effects of this drug in these patients. * Determine the time to progression and survival of patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive oral SarCNU on days 1, 5, and 9. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SarCNU |
Timeline
- Start date
- 2002-01-10
- Primary completion
- 2003-04-15
- Completion
- 2008-09-22
- First posted
- 2003-07-08
- Last updated
- 2020-04-06
Locations
5 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00036660. Inclusion in this directory is not an endorsement.